FDA Issues New Framework for Real-World Evidence on Digital Mental Health Tools

The U.S. Food and Drug Administration has released updated guidance that allows sponsors to submit real-world data and real-world evidence when seeking approval for certain digital health devices aimed at mental health conditions. This approach builds on earlier agency work that recognizes the value of data collected outside traditional clinical trials. The shift matters because it may shorten review times for software-based tools while maintaining standards for data quality. Sponsors can now include such evidence packages as part of their regulatory submissions.

FDA Policy on Real-World Data and Evidence

The agency published final guidance in 2021 that clarifies how real-world data can support regulatory decisions for medical devices, including digital therapeutics. [1] This document explains acceptable sources of real-world evidence and the conditions under which the FDA will consider it. The policy applies to devices that collect ongoing patient information in everyday settings.

FDA’s evolving regulatory framework timeline for real-world evidence and digital mental health tools, highlighting major milestones from 2021 through 2023 and underlying key considerations.

Focus on Digital Health and Mental Health Tools

The FDA established its Digital Health Center of Excellence in 2023 to address software-based products, including those for mental health. [2] The center coordinates efforts to evaluate innovative evidence models for these technologies. A separate framework document from the same year highlights how real-world evidence can support development and approval pathways for digital therapeutics targeting mental health. [3]

Recent Initiatives and Submission Practices

Sponsors may now include real-world evidence in applications to help demonstrate safety and effectiveness. The agency has signaled openness to these data types especially where unmet needs exist, such as in mental health treatment. This practice aligns with broader priorities around modernizing regulatory approaches for software interventions.

What this means

The framework describes how data gathered during routine use of digital tools can supplement traditional studies in FDA reviews. It outlines requirements for data quality and relevance without creating new approval shortcuts. Regulatory pathways for mental health digital therapeutics continue to evolve under this structure.

Limitations

FDA guidance emphasizes that not all real-world data or real-world evidence meets the quality threshold for regulatory decisions. Ongoing challenges include data standardization, patient privacy protections, and validation of software interventions across varied real-world settings. Not every mental health condition or digital therapeutic qualifies for these evidence pathways, and the guidance itself remains subject to further updates.

Key takeaways

• The FDA published final guidance in 2021 on using real-world evidence for medical device decisions, including digital tools. [1]
• The Digital Health Center of Excellence launched in 2023 to advance regulatory approaches for software therapeutics. [2]
• A 2023 framework document supports submission of real-world evidence for mental health digital therapeutics. [3]
• Data quality, standardization, and privacy remain required elements for any evidence package.
• Eligibility for accelerated pathways depends on the specific condition and product characteristics.

Last updated: September 1, 2026